Geode Capital Management LLC Acquires 5,915 Shares of Amedisys, Inc. (NASDAQ:AMED)

Geode Capital Management LLC grew its holdings in Amedisys, Inc. (NASDAQ:AMED) by 1.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 573,020 shares of the health services provider’s stock after purchasing an additional 5,915 shares during the quarter. Geode Capital Management LLC owned approximately 1.75% of Amedisys worth $52,040,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Norges Bank bought a new stake in Amedisys during the 4th quarter valued at $83,061,000. Wealthfront Advisers LLC bought a new stake in shares of Amedisys in the 4th quarter valued at about $72,970,000. Pacer Advisors Inc. grew its position in shares of Amedisys by 11,621.9% in the 4th quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider’s stock worth $50,679,000 after buying an additional 553,435 shares during the last quarter. Birnam Oak Advisors LP bought a new position in shares of Amedisys during the 4th quarter worth approximately $15,832,000. Finally, Calamos Advisors LLC lifted its position in Amedisys by 22.7% during the fourth quarter. Calamos Advisors LLC now owns 487,444 shares of the health services provider’s stock valued at $44,255,000 after acquiring an additional 90,097 shares during the last quarter. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Amedisys Stock Up 0.0 %

NASDAQ:AMED opened at $91.51 on Monday. The company’s 50 day moving average is $92.20 and its two-hundred day moving average is $92.01. The company has a market cap of $3.00 billion, a PE ratio of 36.31, a P/E/G ratio of 1.78 and a beta of 0.89. Amedisys, Inc. has a twelve month low of $82.15 and a twelve month high of $98.95. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). The firm had revenue of $598.05 million during the quarter, compared to analysts’ expectations of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. Analysts anticipate that Amedisys, Inc. will post 4.4 EPS for the current year.

Analyst Ratings Changes

Separately, Stephens reiterated an “equal weight” rating and set a $101.00 price objective on shares of Amedisys in a report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Amedisys has a consensus rating of “Hold” and an average price target of $101.00.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.